Summit Signs $450,000 Zebrafish Deal With A Top Five Pharmaceutical Company

Oxford, England - Summit Corporation plc recently announces the signing of a $450,000 deal with one of the world's top five pharmaceutical companies that will see it using Summit's market-leading zebrafish technology platform as part of its drug discovery and development process.

The undisclosed company will use Summit's zebrafish platform to asses a significant number of its proprietary compounds for safety and toxicity effects in a range of organs that are conserved between the zebrafish and humans including the heart, liver, brain and gut. This extended pilot deal follows the conclusion of an earlier successful validation study conducted between the two companies.

Summit is the world leader in using zebrafish in drug discovery and its innovative technology platform provides invaluable in vivo data of the effects of drug candidates in relevant whole organisms at the earliest stages of drug discovery and development. The in vivo data has the potential to improve the success rate within drug discovery as it allows scientists to make rational decisions about what compounds to advance through the discovery and development process.

SOURCE: Summit Corporation plc